Anne Carpenter: An Open Source Proponent On What Pharma Does And Doesn’t Owe Academia
Anne Carpenter, one of In Vivo’s 2021 Rising Leaders, talks about the growth of open source technology, putting data into action and why pharma deserves to be rewarded for evolving academic findings into marketable products for patients.
You may also be interested in...
The policies have long been Democratic priorities, but of the three, the order’s implicit support for march-in rights might lead to the biggest change.
Legislation to delink PBM payments from drug prices advances in House Energy and Commerce health subcommittee, putting a key pharma priority closer to the finish line. Whether patients will see any benefit remains a worry.
FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues say.